John C. Byrd, MD

John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses updates in the treatment of CLL.

Patient-friendly therapies are changing the lives of patients with CLL.

These oral therapies are active and successfully controlling the disease for an extended period of time.

By combining new, active agents, physicians are moving closer to finding a cure for patients with CLL.

With updates in treatment options, physicians can now start to move away from using chemotherapy to treat patients with CLL.

Videos

John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses updates in the treatment of CLL.


Updates In CLL Treatments

John C. Byrd, MD, a professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses resistance to ibrutinib.

View more about the treatment of chronic lymphocytic leukemia > >

Articles

Resistance to Ibrutinib

John C. Byrd, MD, director of the division of hematology and a CLL specialist at the Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC â€“ James), describes a phase I/Ib trial looking at dinaciclib for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

Dinaciclib is a second-generation selective inhibitor of CDKs 1, 2, 5, and 9

This agent was evaluated in a phase I/Ib expansion study in patients with relapsed or refractory CLL

Unlike early CDK inhibitors, dinaciclib induced a high response rate (65-70%) and durable remissions

John C. Byrd, MD, from OSUCCC â€“ James, describes a phase I/Ib trial looking at dinaciclib for patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

John C. Byrd, MD | Authors

Articles

Updates In CLL Treatments

Resistance to Ibrutinib

A Phase I/Ib Study of the CDK Inhibitor Dinaciclib in CLL